Abstract
Gliomas are primary brain tumors originating from glial cells, representing 30% of all Central Nervous System (CNS) neoplasia. Among them, the astrocytoma grade IV (glioblastoma multiforme) is the most common, presenting an invasive and aggressive profile, with an estimated life expectancy of about 15 months after diagnosis even after treatment with radiation, surgical resection, and chemotherapy. This poor prognosis is related to the presence of the blood-brain barrier (BBB) and multidrug resistance mechanisms that prevent the uptake and retention of chemotherapeutics inside the brain. Gene therapy has been a promising strategy to overcome these treatment limitations since it has the ability to modify the defective genetic information in tumor cells, being able to induce cellular apoptosis and silence the genes responsible for multidrug resistance. Lipidbased nanoparticles, non-viral vectors, have been investigated to deliver genes across the BBB to reach the glioma cell target. Besides, their low immunogenicity, easy production, ability to incorporate ligands to specific target cells, and capacity to carry higher size genes have made the gene therapy based on non-viral vectors a promising glioma treatment. In this context, this review addresses the most common non-viral vectors based on lipid-based nanoparticles used for glioma gene therapy, such as liposomes, solid lipid nanoparticles, nanostructured lipid carriers, and nanoemulsions.
Keywords: Brain tumor, blood-brain barrier, glioblastoma multiforme, nanocarriers, nanomedicine, nanotechnology, nanosystems.
Graphical Abstract
Current Gene Therapy
Title:Gene Therapy Based on Lipid Nanoparticles as Non-viral Vectors for Glioma Treatment
Volume: 21 Issue: 5
Author(s): Marcela Tavares Luiz, Larissa Bueno Tofani, Victor Hugo Sousa Araújo, Leonardo Delello Di Filippo, Jonatas Lobato Duarte, Juliana Maldonado Marchetti and Marlus Chorilli*
Affiliation:
- School of Pharmaceutical Science of Sao Paulo State University (UNESP), Araraquara, Sao Paulo,Brazil
Keywords: Brain tumor, blood-brain barrier, glioblastoma multiforme, nanocarriers, nanomedicine, nanotechnology, nanosystems.
Abstract: Gliomas are primary brain tumors originating from glial cells, representing 30% of all Central Nervous System (CNS) neoplasia. Among them, the astrocytoma grade IV (glioblastoma multiforme) is the most common, presenting an invasive and aggressive profile, with an estimated life expectancy of about 15 months after diagnosis even after treatment with radiation, surgical resection, and chemotherapy. This poor prognosis is related to the presence of the blood-brain barrier (BBB) and multidrug resistance mechanisms that prevent the uptake and retention of chemotherapeutics inside the brain. Gene therapy has been a promising strategy to overcome these treatment limitations since it has the ability to modify the defective genetic information in tumor cells, being able to induce cellular apoptosis and silence the genes responsible for multidrug resistance. Lipidbased nanoparticles, non-viral vectors, have been investigated to deliver genes across the BBB to reach the glioma cell target. Besides, their low immunogenicity, easy production, ability to incorporate ligands to specific target cells, and capacity to carry higher size genes have made the gene therapy based on non-viral vectors a promising glioma treatment. In this context, this review addresses the most common non-viral vectors based on lipid-based nanoparticles used for glioma gene therapy, such as liposomes, solid lipid nanoparticles, nanostructured lipid carriers, and nanoemulsions.
Export Options
About this article
Cite this article as:
Luiz Tavares Marcela , Tofani Bueno Larissa , Araújo Hugo Sousa Victor , Di Filippo Delello Leonardo , Duarte Lobato Jonatas , Marchetti Maldonado Juliana and Chorilli Marlus *, Gene Therapy Based on Lipid Nanoparticles as Non-viral Vectors for Glioma Treatment, Current Gene Therapy 2021; 21 (5) . https://dx.doi.org/10.2174/1566523220999201230205126
DOI https://dx.doi.org/10.2174/1566523220999201230205126 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biocatalytic Synthesis of Terpene Esters and their Biological Activity in
Human Glioma Cells
Current Pharmaceutical Biotechnology Notch Signalling Pathways and Their Importance in the Treatment of Cancers
Current Drug Targets Neurokinin-1 Receptor Antagonists as Anticancer Drugs
Letters in Drug Design & Discovery Advances in Transient Receptor Potential Vanilloid-2 Channel Expression and Function in Tumor Growth and Progression
Current Protein & Peptide Science Advanced Intraoperative MR Imaging
Current Medical Imaging Effect of MRJF4 on C6 Glioma Cells Proliferation and Migration
Central Nervous System Agents in Medicinal Chemistry Potential of Radiolabeled PSMA PET/CT or PET/MRI Diagnostic Procedures in Gliomas/Glioblastomas
Current Radiopharmaceuticals The Anti-Cancer Activity of Noscapine: A Review
Recent Patents on Anti-Cancer Drug Discovery HSP27: Mechanisms of Cellular Protection Against Neuronal Injury
Current Molecular Medicine Hijacking the Hedgehog Pathway in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry MicroRNA Therapeutics: the Next Magic Bullet?
Mini-Reviews in Medicinal Chemistry Natural Products Derived from Traditional Chinese Medicine as Novel Inhibitors of the Epidermal Growth Factor Receptor
Combinatorial Chemistry & High Throughput Screening EGFR-Targeting Monoclonal Antibodies in Head and Neck Cancer
Current Cancer Drug Targets Fluoride Interactions: From Molecules to Disease
Current Signal Transduction Therapy Glioma Therapy: A Novel Insight in the Immunotherapeutic Regime with T11TS/SLFA-3
Central Nervous System Agents in Medicinal Chemistry Systems Cytogenomics: Are We Ready Yet?
Current Genomics Sirtuins Family- Recent Development as a Drug Target for Aging, Metabolism, and Age Related Diseases
Current Drug Targets Role of ncRNAs in Development, Diagnosis and Treatment of Human Cancer
Recent Patents on Anti-Cancer Drug Discovery Mitochondrial Superoxide Dismutase - Signals of Distinction
Anti-Cancer Agents in Medicinal Chemistry Advances in Nanomedicine Towards Clinical Application in Oncology and Immunology
Current Pharmaceutical Biotechnology